The Wall Street Buy List

4 Recommendations

"Actions speak louder than words."

It's an old saying, with more than a grain of truth to it, I'll warrant. So why is it that when the Wall Street firms merely "initiate coverage" or "upgrade" their ratings on a company, that gets all the news coverage? After all, those are only words, when what really matters is how the big boys act. Luckily for Wall Street watchers, finding out which professionals put their money where their corporate mouthpieces are has become relatively easy in this Internet age of ours. All we have to do is read MSN Money's list of which companies the Street is most actively buying.

But once we've done that, what next? After all, "Monkey see, monkey do" may not make for the soundest of investment strategies. That's where Motley Fool CAPS can help. The Fool's newest venture into the realm of collective intelligence collects ratings from more than 60,000 lay and professional analysts, then overweights the most successful raters' opinions to come up with a "CAPS rating" from one to a maximum five stars. If Wall Street's buying, and the smartest investors in Fooldom say they're right to do so, Fools should pay attention.

Let's meet today's list of contenders:

Currently Fetching

CAPS Rating (out of 5)

BioCryst Pharmaceuticals  (Nasdaq: BCRX)

$12.51

**

Innophos Holdings  (Nasdaq: IPHS)

$14.73

**

HealthTronics  (Nasdaq: HTRN)

$4.76

*

Resource Capital  (NYSE: RSO)

$11.34

***

American Real Estate Partners  (NYSE: ACP)

$118.80

*

Enzo Biochem  (NYSE: ENZ)

$18.21

*

Avalon Pharmaceuticals (Nasdaq: AVRX)

$5.95

Not rated

Companies are selected from the "Institutional Ownership Up Last Month" list published on MSN Money on the Saturday following close of trading last week. Price increase and current pricing also provided by MSN Money on the same date. CAPS ratings from Motley Fool CAPS.

Wall Street vs. Main Street
"What were you thinking?!" That seems to be the question Main Street investors want to ask the experts this week. Out of these seven stocks that Wall Street was buying hand over fist over the last 30 days, only one gets so much as an ambivalent three-star rating from investors on CAPS. Although with one stock, Avalon Pharma, attracting too little interest to merit any rating at all, you never know. It might blow the curve (once more people notice it exists).

In the meantime, though, we've got no real contenders today. Wall Street may like these stocks, and if so ... it can have 'em.

Build-a-bull, anyone?
Or can it? With well more than 60,000 investors currently signed up for CAPS, earning their investing stripes in the biggest stock- and analyst-rating service online, surely there's someone out there who can figure out what Wall Street sees in these stocks. Are you that someone?

If that sounds like a rhetorical question, it isn't. You see, on CAPS, we depend on our community of investors to tell us what's hot and what's not -- and to explain why, as well. If you know a reason why your fellow investors should be bullish on any of the seven stocks named above, we're all ears. Come on over to CAPS and give us your best pitch.

Motley Fool CAPS: It's fun, it's free, and it just might make you famous.

Fool contributor Rich Smith does not own shares of any company named above. You can find him on CAPS, publicly pontificating under the handle TMFDitty, where he's currently ranked No. 308 out of more than 60,000 players. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 536202, ~/articles/articlehandler.aspx, 11/22/2008 4:47:53 PM,

Sign up for FREE Motley Fool site access to keep reading:

“The Wall Street Buy List”

Signing up allows you to comment on articles and on the discussion boards.

It's completely FREE and will take only 10 seconds.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Related Tickers

Unavailable

Major Indices

S&P 500800.03+6.32%
DJIA8,046.42+6.54%
NASD1,384.35+5.18%
Updated: 4:07:36 PM
Sponsored by:

The Motley Poll

What changes are you making to your portfolio?

Sponsored by: